Skip to content
http://lifestyle.lmcordoba.com.ar/
Animals
Auto
Beauty & Style
Business News
Entertainment
Food
Health
Home & Family
Podcasts
Tech
Travel
Author:
Acurx Pharmaceuticals, Inc.
FDA Provides Further Regulatory Guidance to Acurx Pharmaceuticals for the Ibezapolstat Clinical Development Program, Including the Potential for a Single-Phase 3-Trial Registration Plan and a Trial Design to Support Both Treatment and Reduction of Recurrence of C. difficile Infection
August 3, 2026
Acurx Pharmaceuticals Announces Scientific Poster Presentation of Ibezapolstat’s Microbiome Preservation Data in Multiply-recurrent C. difficile Infection
July 14, 2026
Acurx Pharmaceuticals to Discuss Second Quarter 2026 Financial Results on August 14, 2026 Conference Call and Provide Business Update
July 8, 2026
Acurx Pharmaceuticals Announces Presentation of Results from Leiden University Medical Center Public-Private Partnership for Its DNA pol IIIC Inhibitors at the Leiden Early Drug Discovery & Development (LED3) Scientific Conference
June 16, 2026
Acurx Pharmaceuticals, Inc. Reports First Quarter 2026 results and Provides Business Update
May 23, 2026
Acurx Announces Scientific Poster Presentation of its DNA pol IIIC Inhibitors’ Microbiome Evaluation at ESCMID Global 2026
May 22, 2026
Acurx Pharmaceuticals to Present at the Alliance Global Partners (A.G.P) Healthcare Company Showcase
May 22, 2026
Acurx Pharmaceuticals to Discuss First Quarter 2026 Financial Results on May 12, 2026 Conference Call and Provide Business Update
May 19, 2026
Acurx Pharmaceuticals, Inc. Announces Closing of up to $7.1 Million Registered Direct Offering Priced At-The-Market Under Nasdaq Rules
April 29, 2026
Acurx Pharmaceuticals, Inc. Announces up to $7.1 Million Registered Direct Offering Priced At-The-Market Under Nasdaq Rules
April 29, 2026
1
2
Next Page
→